CTLA4 and neoplasm: So far, the study by Zamarin et al. has shown that tumors in type I receptor knockout mice IFNAR1 -/-, were resistant to anti-tumor effects of NDV and anti-CTLA-4 [62], indicating that the combination therapy was dependent on type I IFN signaling pathways.